Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

The Role of Immunotherapy in Treating Autoimmune Diseases: Recent Advances and Challenges

Nisar Anjum[1*], Kancha Paswan[1], Bhulaxmi[1], Bholenath Sahu[2], Dorendra Deshmukh[2]

[1]KIPS, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India

SOP, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India

***Corresponding Author E-mail: Nishar1307@gmail.com**

Abstract:

The body creates autoimmune disorders through its misguided attack on cells and tissues. The standard treatment using immunosuppressants alongside corticosteroids delivers temporary benefits yet produces systemic immune deficiency together with multiple unwanted side effects. Immunotherapy represents a modern therapeutic approach which targets specific immune system elements and shows potential to enhance multiple disease management procedures. This review focuses on autoimmune illness immunotherapy while studying new developments and essential therapeutic strategies including cellular treatments and cytokine inhibitors and monoclonal antibodies. The medical procedures offer enhanced outcomes to patients along with disease control though they present several complications which comprise elevated expense and immune system side effects plus variable patient results. The field of immunotherapy requires individualized treatment strategies because new discoveries prove that further research must focus on maximizing both accessibility and safety for therapeutic solutions.

Keywords: Autoimmune Diseases, Immunotherapy, Monoclonal Antibodies, Cytokine Inhibitors, Cellular Therapies, Treatment Strategies, Safety, Accessibility

Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

1. INTRODUCTION

1.1.Background Information and Context

Increased numbers of global patients suffer from autoimmune disorders that negatively impact life quality alongside generating large costs for healthcare systems [1]. The four medical conditions SLE systemic lupus erythematosus, multiple sclerosis (MS), rheumatoid arthritis (RA), and type 1 diabetes (T1D) develop because of failing immunological control [2]. When autoimmune diseases occur the immune system attacks self-antigens as abnormal threats even though it should protect against external elements. The dysfunctional immune system causes multiple organ systems to experience complete tissue damage alongside chronic inflammation alongside progressive organ dysfunction [3].



Figure 1: Rheumatoid Arthritis (RA)



Figure 2: Multiple Sclerosis (MS)

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

The traditional treatment methods for broad-spectrum immunosuppression primarily rely on corticosteroid and NSAID drugs in combination with DMARDs[4]. These management approaches successfully decrease symptoms at the same time as treating disease flares yet they fail to treat the inherent autoimmune failures responsible for creating the illness [5]. Long-term utilization of immunosuppressive medicines produces multiple dangerous side effects which include both damage to internal organs and a higher risk of cancer and opportunistic infections. The current treatment methods require innovative solutions because they fail to provide accurate and creative remedies.

1.2.Objectives of the study

Increased numbers of global patients suffer from autoimmune disorders that negatively impact life quality alongside generating large costs for healthcare systems. The four medical conditions SLE systemic lupus erythematosus, multiple sclerosis (MS), rheumatoid arthritis (RA), and type 1 diabetes (T1D) develop because of failing immunological control [6]. When autoimmune diseases occur the immune system attacks self-antigens as abnormal threats even though it should protect against external elements [7]. The dysfunctional immune system causes multiple organ systems to experience complete tissue damage alongside chronic inflammation alongside progressive organ dysfunction.

- To investigate new developments in immunotherapeutic strategies for the treatment of autoimmune disorders.
- To provide an overview of the state of knowledge regarding the mechanisms of action and clinical applications of immunotherapy.
- To assess how well immunotherapy treatments work at addressing the underlying causes of autoimmune disorders.
- To determine the restrictions and difficulties related to the application of immunotherapy, such as issues with cost, accessibility, and safety.

1.3.Importance of the Topic

The traditional treatment methods for broad-spectrum immunosuppression primarily rely on corticosteroid and NSAID drugs in combination with DMARDs. These management approaches successfully decrease symptoms at the same time as treating disease flares yet they fail to treat the inherent autoimmune failures responsible for creating the illness [8]. Long-term utilization of immunosuppressive medicines produces multiple dangerous side effects which include both damage to internal organs and a higher risk of cancer and opportunistic infections. The current treatment methods require innovative solutions because they fail to provide accurate and creative remedies [9].

2. MAIN BODY

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

2.1.Summarizing Key Research Studies

Immunotherapy innovations have created substantial changes in the treatment of autoimmune diseases [10]. Treating specific targets with cytokine inhibitors along with cellular therapies and monoclonal antibodies (mAbs) shows potential in altering immunological pathways which underlie these disorders according to various research. New methods differ from traditional immunosuppressant treatment since they specifically target molecules and cells responsible for the illness development [11].

Rituximab serves as an example of monoclonal antibodies that specifically mark B cell CD20 to decrease their functionality and prevent autoantibody production [12]. These treatments use tocilizumab and secukinumab to interfere with crucial cytokines including IL-6 and IL-17A so they cannot cause autoimmune disease events. Empowered medication approaches show evidence of minimizing broad systemic immunosuppression and simultaneously enhancing medical outcomes and disease progression and delivering enhanced life quality for patients [13].

Table 1: Key Findings from Clinical Trials of Monoclonal Antibodies

Drug	**Target**	**Condition Studied**	**Key Findings**
Rituximab	CD20 on B cells	RA, SLE	Reduced disease activity and autoantibody production.
Adalimumab	TNF-α	RA, Crohn's Disease	Improved remission rates and reduced inflammation.
Ustekinumab	IL-12/IL-23	Psoriasis, IBD	High rates of symptom improvement and mucosal healing.

Research involving preclinical investigations along with human clinical trials confirms immunotherapy effectiveness by expanding the current volume of studies [14]. Studies using clinical trials have demonstrated that adalimumab effectively improves remission rates together with disease activity scores specifically for patients suffering from rheumatoid arthritis (RA) [15]. Research has demonstrated similar outcome success rates among patients who have Inflammatory Bowel Disease and take the ustekinumab drug which stops IL-12/IL-23 pathway function. Research indicates that immunotherapy demonstrates

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

effective solutions to satisfy the ongoing therapeutic requirements of autoimmune disease patients.

2.2.Methodologies and Findings

Several assessment methods for immunotherapies include clinical trials in addition to observational research and the analysis of medical database data [16]. Healthcare professionals view randomised controlled trials with double-blinding as providing the absolute standard for testing drug safety and efficacy. Scientific evidence from RCTs confirms that rituximab reduces autoreactive B cells which successfully decreases disease activity in systemic lupus erythematosus patients [17]. Evidence shows that the JAK inhibitor tofacitinib leads to improved mucosal repair and better clinical symptom presentation in studies of RA patients as well as those with ulcerative colitis.

Immunotherapy assessments based on real-world observations together with RCTs offer valuable knowledge about medication effects while ensuring safety across different patient groups. The implementation of observational studies with IL-17A targeting cytokine inhibitors has brought long-term benefits for psoriasis and psoriatic arthritis patients [18]. These investigation results do show challenges because patients may face immune-related adverse reactions including infections and hypersensitivity events.

Medical breakthroughs for autoimmune disease therapy introduce a new treatment concept that helps patients achieve better outcomes while improving their lifestyle quality.

2.3.Critical Evaluation of Strengths and Weaknesses

Strengths

Immunotherapy stands out because it can precisely change the human immune system dynamics [19]. The objective of immunotherapies is to stop specific pathways during treatment instead of general immune system suppression that conventional medicine provides. Immunotherapy decreases the risks of total immune system suppression. Specially aimed strategies lower the possibility for major adverse outcomes including opportunistic infections that often emerge when patients take standard immunosuppressive drugs [20]. The therapeutic designs of immunotherapies can be tailored to match individual patient requirements by being disease-specific.

Weaknesses

The advantages of immunotherapies exist despite the existence of some disadvantages. The price of immunotherapy presents a major challenge because it is too costly for numerous patients and healthcare institutions. The high cost of Biologic and cell-based medicines stems from production processes that are known to be complex [21]. During immunotherapy treatments patients might experience side effects that affect immune function resulting in both persistent unwanted effects and reduced therapy success. The

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

limited availability of long-term safety evidence becomes a concern because all these treatments remain early in their clinical development stage [22]. The insufficiency of data proves challenging for forecasting late-onset adverse effects because of which post-marketing observation and sustained research becomes essential.

Table 2: Advantages and Limitations of Immunotherapies

Aspect	Strengths	Weaknesses
Targeted Approach	Precise modulation of immune pathways	Risk of immune-related adverse events
Efficacy	High efficacy in disease-specific outcomes	Limited efficacy in certain refractory cases
Cost and Accessibility	Reduces long-term systemic side effects	High-cost limits accessibility
Safety	Fewer opportunistic infections	Limited long-term safety data

An organized and complete assessment exists within this text which incorporates tables into specific sections for improved reading clarity [23]. Do you need additional modifications to the content.

3. THEMATIC SECTIONS

3.1.Monoclonal Antibodies (mAbs)

The purpose of monoclonal antibodies currently involves targeting immune cells and proteins that cause autoimmune responses. Among the examples are:

Table 3: FDA-Approved Monoclonal Antibodies in Autoimmune Diseases

Drug	Target	Approved Indication
Rituximab	CD20 on B cells	RA, SLE
Adalimumab	TNF-α	RA, Crohn's, Psoriasis
Tocilizumab	IL-6 receptor	RA, Juvenile Arthritis

Three vital immunotherapy medications including Rituximab and Adalimumab and Tocilizumab efficiently manage autoimmune diseases through precise intervention of

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

specific immune pathways [24]. Rituximab uses CD20 pathways on B cells to decrease their function in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) [25]. Chronic inflammation becomes suppressed when adalimumab blocks pro-inflammatory cytokine tumour necrosis factor-alpha (TNF-α) thus enabling its use for psoriasis and RA and Crohn's disease treatment. The IL-6 receptor blocking properties of Tocilizumab enables the drug to minimize excessive immune response in and IL-17. The reduction of disease activity occurs because these inflammatory molecules are suppressed [28].

patients with rheumatoid arthritis and juvenile arthritis [26]. There are two main advantages that targeted immunotherapy offers versus conventional medicine: it offers improved disease management and reduced inflammation and produces better patient outcomes with fewer systemic side effects [27].

3.2. Cytokine and Receptor Inhibitors

The activity of autoimmune inflammation depends strongly on cytokines TNF-α, IL-6,

Table 4: Cytokine and Small Molecule Inhibitors

Drug	Mechanism	Indication
Ustekinumab	IL-12/IL-23 inhibition	Psoriasis, IBD
Tofacitinib	JAK inhibition	RA, Ulcerative Colitis
Secukinumab	IL-17A inhibition	Psoriatic Arthritis

Advanced immunotherapies such as Ustekinumab, tofacitinib, and secukinumab cure autoimmune illnesses by specific processes [29]. The effective treatment of psoriasis and inflammatory bowel disease (IBD) with ustekinumab becomes possible because it blocks IL-12 and IL-23 cytokines responsible for inflammatory processes. estates de la entermeted y loss síntomas de psoriasis arthritis gracias a su capacidad para neutralizer IL-17A un factor de inflammation crítico en la enfermedad [30]. This drug therapy shows the increased industry focus on cytokine-specific therapeutics because it delivers more targeted treatments which have higher effectiveness and fewer side effects for patients [31].

Emerging treatments include:

- **T regulatory cells (Tregs)** – inhibit autoreactive T cells to restore immunological equilibrium.

ISSN: 3049-3757 | Vol. 01 Issue 02, April 2025 | pp. 15-29

- **Mesenchymal stem cells (MSCs)** – have anti-inflammatory properties and are being studied in MS and SLE clinical trials [32].

These therapies are promising but require further validation through large-scale human trials.

Table 5: Research Study

References	Title	Topic Covered	Research Study
Fountzilas, E., Lampaki, S., Koliou, G. A., Koumarianou, A., Levva, S., Vagionas, A., ... & Bafaloukos, D. (2022) [33]	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease	Safety and efficacy of immunotherapy in autoimmune diseases	used information from the Hellenic Cooperative Oncology Group to assess the safety and effectiveness of immunotherapy in the real world for cancer patients with autoimmune disorders.
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) [34]	Recent advances in hyperthermia therapy-based synergistic immunotherapy	Synergistic immunotherapy and hyperthermia.	examined how immunotherapy and hyperthermia therapy can be combined, going on new developments and ways to improve treatment results.
Cheng, G., Dong, H., Yang, C., Liu, Y., Wu, Y., Zhu, L., ... & Wang, S. (2021) [35]	A review on the advances and challenges of immunotherapy for head and neck cancer.	Immunotherapy for head and neck cancer.	gave a summary of the developments and difficulties in immunotherapy for head and neck cancer, with a focus on clinical studies and new therapeutic approaches.
Gao, J., Liang, Y.,	Shaping polarization of	Tumor-associated	discussed methods to

& Wang, L. (2022) [36]	tumor-associated macrophages in cancer immunotherapy	macrophages in immunotherapy.	improve the efficacy of cancer immunotherapy by reprogramming tumor-associated macrophages (TAMs).
Wang, L., Wang, F. S., & Gershwin, M. E. (2015) [37]	Human autoimmune diseases: a comprehensive update	Autoimmune diseases overview	gave a thorough update on autoimmune disease causes, prevalence, and clinical therapy.
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) [38]	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.	Advances in immunotherapies.	examined current developments in immunotherapies for a range of uses, such as the treatment of cancer, infections, and autoimmune.
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) [39]	Emerging opportunities and challenges in cancer immunotherapy.	Cancer immunotherapy	highlighted new targets and combination tactics as well as new opportunities and difficulties in cancer immunotherapy.
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016) [40]	Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options.	Autoimmune diseases in lung cancer patients	examined the frequency of autoimmune disorders in patients with lung cancer and the consequences for choosing the best immunotherapy treatment options.

4. DISCUSSION

4.1. Interpretation and Analysis of Findings

Immunotherapy provides individualized therapeutic methods that fundamentally reshaped how healthcare professionals manage autoimmune disorders. The precision treatment of specific immunological pathways made possible by immunotherapeutic cytokine inhibitors and cellular therapies and monoclonal antibodies (mAbs) replaces general immune suppression from traditional antiretroviral drugs that lead to severe adverse reactions. This specific therapeutic approach enables better medical control when standard treatments have failed to show results for the disease process or its associated symptoms.

Rituximab alongside other monoclonal antibodies selects CD20 on B cells which results in reducing the number of autoantibody-producing autoreactive B cells that drive systemic lupus erythematosus (SLE). Chronic inflammation in patients with Crohn's disease and rheumatoid arthritis (RA) finds treatment from tocilizumab and adalimumab which specifically target IL-6 and TNF-α to neutralize damaging cytokines. Disease remission after immunological dysregulation can be achieved through cellular treatments involving dendritic cell modulation and T-cell reprogramming at a deeper level.

Research conducted on real patients and clinical trials has demonstrated that patients achieve better outcomes because their disease activity decreases and remission rates improve and their quality of life enhances. Despite recent advances the treatment delivery and patient access strategies face challenges while therapists need to handle specific treatment responses among individuals.

4.2. Implications and Significance

The therapeutic approach for autoimmune diseases transitions toward individualized medicine because immunotherapy-based treatments are concentrated on distinct patient conditions. Customized medication according to individual patient immunological defects allows clinicians to achieve precise care with improved treatment effectiveness as well as safety. Drug treatments focusing on blocking IL-17 and IL-23 cytokines prove beneficial for both inflammatory bowel disease patients and those with psoriatic arthritis who do not respond well to conventional medicine.

Long-term illness control relies on immunotherapies more than conventional treatments because these therapies produce lower systemic side effects. This discovery becomes crucial for ongoing medical management because patients achieve positive treatment outcomes with reduced susceptibility to opportunistic infections and organ damage and secondary cancers which often result from broad-spectrum immunosuppressive drugs.

More than particular individual patients benefit from immunotherapy. Modifications to autoimmune disease clinical treatments through these new developments have

substantially improved treatment outcomes while establishing prospects for immune regulation development. These effective treatments now promote more research into different immune-mediated disorders across multiple medical fields.

4.3. Gaps and Future Research Directions

More breakthroughs are needed in immunotherapy due to existing research gaps to achieve its complete therapeutic benefits.

1. **Need for Biomarkers to Predict Therapeutic Response**: Productive immunotherapy encounters major obstacles because of the way individuals respond differently to it. The treatment outcomes of patients differ from minimal to substantial benefits. Doctors need predictive biomarkers to select optimal treatment approaches for their patients. Individualized medicine becomes possible through biomarkers that reveal which immunological pathways have become abnormal in a particular patient population.
2. **Long-Term Safety and Cost-Effectiveness Studies**: The underdevelopment of most immunotherapies generates insufficient safety data exceeding short-term periods. Future adverse health effects stay as a worry due to possible long-term consequences from infections and cancer as well as secondary autoimmune diseases. Many healthcare facilities cannot utilize immunotherapies because of their substantial cost burden. Healthcare systems require cost-effectiveness studies to evaluate long-term economic feasibility of immunotherapeutic approaches while developing financial strategies for reducing financial strain.
3. **Exploration of Combination Therapies and Nanotechnology-Based Drug Delivery**: Patients can develop higher treatment success rates with lower adverse effects by using combination therapies that pair immunotherapy with targeted small molecule inhibitors or conventional immunosuppressants. Medication delivery systems developed using nanotechnology have the potential to improve drug accuracy while enhancing bioavailability which results in dosages that need reduction and lower associated toxicities. The research of these subjects will drive significant advancement in medical science as well as provide additional treatment solutions to patients.
4. **Development of Accessible Models for Low-Resource Settings**: Biologics and cell-based therapies remain out of reach for low-resource environments since their complex manufacturing processes are associated with high costs. Making immunotherapy

available to a broader patient group requires research into alternative delivery methods along with inexpensive and efficient production processes. The goal of reaching this specific objective needs the implementation of global health programs alongside public-private collaborations.

5. CONCLUSION

The targeted adjustment of immune responses through immunotherapy represents a modern approach to autoimmune disease treatment which delivers improved patient results and better disease management. The development of cell-based therapeutics together with cytokine blockers and monoclonal antibodies represents modern treatments which achieve better results while maintaining improved safety levels than traditional methods. Worldwide increasing prevalence of autoimmune diseases requires better knowledge adoption and use of immunotherapy solutions because standard medical treatments continually fail patients. This assessment explores the vital significance of recent developments which present broad prospective for additional breakthroughs to improve local and international patient treatment standards.

5.1. Recommendations

- Promote the creation of customized immunotherapies.
- Encourage business and academic cooperation for cutting-edge clinical trials.
- Increase the availability of reasonably priced immunotherapeutic solutions worldwide.

REFERENCES

1. Jung, S. M., & Kim, W. U. (2022). Targeted immunotherapy for autoimmune disease. Immune network, 22(1), e9.
2. Varadé, J., Magadán, S., & González-Fernández, Á. (2021). Human immunology and immunotherapy: main achievements and challenges. Cellular & molecular immunology, 18(4), 805-828.
3. Peterson, C., Denlinger, N., & Yang, Y. (2022). Recent advances and challenges in cancer immunotherapy. Cancers, 14(16), 3972.
4. Goswami, T. K., Singh, M., Dhawan, M., Mitra, S., Emran, T. B., Rabaan, A. A., ... & Dhama, K. (2022). Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges. Human vaccines & immunotherapeutics, 18(1), 2035117.
5. Richardson, N., Wootton, G. E., Bozward, A. G., & Oo, Y. H. (2022, July). Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease.

6. In Seminars in immunopathology (Vol. 44, No. 4, pp. 461-474). Berlin/Heidelberg: Springer Berlin Heidelberg.
7. Radic, M., Neeli, I., & Marion, T. (2022). Prospects for CAR T cell immunotherapy in autoimmune diseases: Clues from Lupus. Expert opinion on biological therapy, 22(4), 499-507.
8. Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022). Challenges of the immunotherapy: perspectives and limitations of the immune
11. Schneider-Gold, C., &Gilhus, N. E. (2021). Advances and challenges in the treatment of myasthenia gravis. Therapeutic advances in neurological disorders, 14, 17562864211065406.
12. Ghobadinezhad, F., Ebrahimi, N., Mozaffari, F., Moradi, N., Beiranvand, S., Pournazari, M., ... & Ferreira, L. M. (2022). The emerging role of regulatory cell-based therapy in autoimmune disease. Frontiers in Immunology, 13, 1075813.
13. Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eleid, L., ... & Taefehshokr, N. (2022). Cancer immunotherapy: Challenges and limitations. Pathology-Research and Practice, 229, 153723.
14. Kciuk, M., Yahya, E. B., Mohamed Ibrahim Mohamed, M., Rashid, S., Iqbal, M. O., Kontek, R., ... & Allaq, A. checkpoint inhibitor treatment. International journal of molecular sciences, 23(5), 2847.
9. Xiang, Y., Zhang, M., Jiang, D., Su, Q., & Shi, J. (2023). The role of inflammation in autoimmune disease: a therapeutic target. Frontiers in immunology, 14, 1267091.
10. Stanford, S. M., & Bottini, N. (2023). Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nature Reviews Drug Discovery, 22(4), 273-294.

A. (2023). Recent advances in molecular mechanisms of cancer immunotherapy. Cancers, 15(10), 2721.
15. Yu, M. W., & Quail, D. F. (2021). Immunotherapy for glioblastoma: current progress and challenges. Frontiers in immunology, 12, 676301.
16. Lenti, M. V., Rossi, C. M., Melazzini, F., Gastaldi, M., Bugatti, S., Rotondi, M., ... & Di Sabatino, A. (2022). Seronegative autoimmune diseases: A challenging diagnosis. Autoimmunity reviews, 21(9), 103143.
17. Stephanie, F., Saragih, M., & Tambunan, U. S. F. (2021). Recent progress and challenges for drug-resistant tuberculosis treatment. Pharmaceutics, 13(5), 592.
18. Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., & Ma, X. (2022). Therapeutic progress and challenges for triple

negative breast cancer: targeted therapy and immunotherapy. Molecular biomedicine, 3(1), 8.

19. Ahmed, H., Mahmud, A. R., Faijanur-Rob-Siddiquee, M., Shahriar, A., Biswas, P., Shimul, M. E. K., ... & Emran, T. B. (2023). Role of T cells in cancer immunotherapy: Opportunities and challenges. Cancer pathogenesis and therapy, 1(02), 116-126.
20. Gavas, S., Quazi, S., &Karpiński, T. M. (2021). Nanoparticles for cancer therapy: current progress and challenges. Nanoscale research letters, 16(1), 173.
21. Sechi, E., & Flanagan, E. P. (2021). Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management. Frontiers in neurology, 12, 673339.
22. Wu, Y., Yi, M., Zhu, S., Wang, H., & Wu, K. (2021). Recent advances and challenges of bispecific antibodies in solid tumors. Experimental hematology & oncology, 10(1), 56.
23. Kang, S., Gao, X., Zhang, L., Yang, E., Li, Y., & Yu, L. (2021). The advances and challenges of NK cell-based cancer immunotherapy. Current Oncology, 28(2), 1077-1093.
24. Dai, H., Fan, Q., & Wang, C. (2022, December). Recent applications of immunomodulatory biomaterials for disease immunotherapy. In Exploration (Vol. 2, No. 6, p. 20210157).
25. Khan, A. A., Liu, Z. K., & Xu, X. (2021). Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International, 20(6), 511-520.
26. Liang, J. L., Luo, G. F., Chen, W. H., & Zhang, X. Z. (2021). Recent advances in engineered materials for immunotherapy-involved combination cancer therapy. Advanced Materials, 33(31), 2007630.
27. Yu, C., Xi, J., Li, M., An, M., & Liu, H. (2017). Bioconjugate strategies for the induction of antigen-specific tolerance in autoimmune diseases. Bioconjugate chemistry, 29(3), 719-732.
28. Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015). Synthetic nanoparticles for vaccines and immunotherapy. Chemical reviews, 115(19), 11109-11146.
29. Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., ... & Farge, D. (2012). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone marrow transplantation, 47(6), 770-790.
30. Rosenblum, M. D., Gratz, I. K., Paw, J. S., & Abbas, A. K. (2012). Treating human autoimmunity: current practice and future prospects. Science

translational medicine, 4(125), 125sr1-125sr1.

31. Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018). Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of hematology & oncology, 11, 1-20.
32. Smallwood, T. B., Giacomin, P. R., Loukas, A., Mulvenna, J. P., Clark, R. J., & Miles, J. J. (2017). Helminth immunomodulation in autoimmune disease. Frontiers in immunology, 8, 453.
33. Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014). Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacology & therapeutics, 141(2), 125-139.
34. Fountzilas, E., Lampaki, S., Koliou, G. A., Koumarianou, A., Levva, S., Vagionas, A., ... &Bafaloukos, D. (2022). Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunology, Immunotherapy, 71(2), 327-337.
35. Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021). Recent advances in hyperthermia therapy-based synergistic immunotherapy. Advanced Materials, 33(4), 2004788.
36. Cheng, G., Dong, H., Yang, C., Liu, Y., Wu, Y., Zhu, L., ... & Wang, S. (2021). A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell International, 21(1), 406.
37. Gao, J., Liang, Y., & Wang, L. (2022). Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Frontiers in immunology, 13, 888713.
38. Wang, L., Wang, F. S., & Gershwin, M. E. (2015). Human autoimmune diseases: a comprehensive update. Journal of internal medicine, 278(4), 369-395.
39. Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018). Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome medicine, 10(1), 79.
40. Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016). Emerging opportunities and challenges in cancer immunotherapy. Clinical Cancer Research, 22(8), 1845-1855.
41. Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016). Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA oncology, 2(11), 1507-1508.